Biomarkers
NSCLC, tumor, death, Tumor, CTS, PD
NON-SMALL CELL LUNG CANCER, TUMOR, TUMOR, DISEASE, ADHESION, NSCLC
Tumor PD-L1 expression was measured by immunohistochemistry. Among 7 responders, including the delayed responder, only 1 patient had high PD-L1 expression (≥ 50%), 5 patients had PD-L1 scores in the range of 1 to 30%, and 1 patient was PD-L1 negative. PD-L1 expression did not correlate with efficacy based upon this small sample set (Fig. DNA sequencing was performed for the subset of tumor samples with sufficient tissue remaining (Genetic Variants and RNA Signatures in NSCLC Cohort. Abbreviations: BOR, best overall response; CTS, change in tumor size; NE, not evaluable; OS, overall survival; PD, progressive disease; PD-L1, programmed death ligand 1; PFS, progression-free survival; PR, partial response; TGF-β, transforming growth factor beta; TMB, tumor mutation burden. *pseudo-progressor patientBaseline RNA expression data associated with 12 tumor samples was used to evaluate previously identified expression signatures associated with immune function and TGF-β biology, including the T-cell inflamed signature and TGF-β pathway genes [The RNA expression profile of 19 tumor samples were analyzed (12 baseline samples vs 4 collected on C1D15 and 3 on C2D1) to look for pharmacodynamics (treatment driven) expression changes. Of the 6 paired samples, 3 were baseline versus C1D15 and 3 were baseline versus C2D1. Genes associated with interferon gamma response were upregulated, while repressed genes were associated with cell adhesion (Fig. Modulation of Tumor RNA Expression in NSCLC Cohort. Abbreviations: CxDx, Cycle x Day x; FC, fold change; IFNG.RES, interferon gamma response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease. Shapes represent 6 paired samples; the star represents the pseudo-progressor patient; filtering criteria: Serum proteins (Serum Interferon Gamma Induced Protein 10, Interleukin-2 Receptor Alpha, and Monokine Induced by Gamma Interferon in NSCLC Cohort. Abbreviations: NSCLC, non-small cell lung cancer; CxDx, Cycle X Day X; IP-10, interferon gamma-induced protein 10; MIG, monokine induced by gamma interferon